The Israel Boycott Certificate in Iraqi Company Registration

1. Key takeaways

The Israel boycott certificate is one of the official documents the Iraqi Registration Department requires from device companies. According to Section D item 5 of the Drug Registration Regulations published by the Registration Department of the Technical Affairs Directorate of the Iraqi Ministry of Health, the original reads «Certification letter regarding the boycott with Israel» — a certification letter concerning the boycott with Israel, listed alongside the company registration form, the quality assurance system certificate, the country-of-origin manufacturer registration certificate, the product catalogue, and the company registration fee of USD 1,000. It is a commercial document requirement appearing at the level of a document checklist, and this article makes only an objective statement about it. Where a company’s own situation is inconsistent with the requirement, the compliant path applies: truthful declaration, advance written communication with the Iraqi purchaser or agent, and legal advice where necessary. GRZAN does not provide any evasion or workaround.

• Section D item 5 asks for a certification letter regarding the boycott with Israel, without naming a template, an issuing body or a legalization chain.
• Its position as item 5 of a six-item list makes it a registration requirement, not a procedural explanation.
• Article 105 of the Public Health Law authorizes the Ministry of Health to issue regulations, instructions and announcements, the general enabling source for ministerial document demands.
• The specific legal basis, the issuing body and any format template were not found in any official gazette provision this round, so no statutory inference is drawn here.

2. Legal basis

The table below lists the sources cited in this article together with their document numbers, publication dates and the provisions relied upon.

Source grading: the Drug Registration Regulations is graded secondary and must not be cited as a legal provision (hosted at https://pharmexcil.com/uploadfile/ufiles/380351111_drug_regpdf.pdf; the official original was not obtained). The Public Health Law is graded primary and verified. The Country Profile 2020 is graded primary, indirectly verified (the source site was blocked and the content was obtained through indexed snippets). As for the specific legal source of this documentary requirement, the issuing body and any format template, no official gazette provision was obtained this round, including searches of the Official Gazette, so this article draws no inference at the level of statutory text.

Excerpts of the original provisions:

• Section D item 5 (English original): «Certification letter regarding the boycott with Israel.» — literally, a certification letter; the document specifies no issuing body, validity period or legalization chain.
• Context of Section D: this item stands alongside the company registration fee of USD 1,000 as items 5 and 6 of a complete list, showing that its place in the process is a registration requirement, not a procedural note.
• Article 105 of the Public Health Law: regulations, instructions and announcements may be issued to facilitate the implementation of the provisions of this law — the enabling source for the Ministry of Health’s various ministerial document requirements.

3. Expert insights

Insight 1 | This is the only item in the checklist entirely unrelated to the technical attributes of the product. The first four items point to company identity, system, qualification and product scope; the sixth is the fee; the fifth points to the commercial stance of the trading entity. To read it as a technical document is a mistake — it is closer to a declaratory statement. GRZAN files it in the same group as payment receipts and commitment letters.

Insight 2 | Cross-border comparison: the forms declaratory statements take across the Middle East. The Declaration of Conformity and stakeholder disclosures required for Saudi SFDA device market authorization, the pricing structure and agent declarations required by the UAE’s MOHAP, and the technical conformity declarations required by the GSO are all documents signed by the company itself, which bears the legal responsibility. The Iraqi item is of the same family in form — self-issued and self-responsible. The difference is that its content concerns the trading counterpart, which makes it more sensitive.

Insight 3 | Debunking: the circulating claim that the boycott certificate requires dual certification by CCPIT and China’s Ministry of Foreign Affairs has no basis. Section D item 5 is a pair of phrases with nothing about official certification; the only item in Section D bearing the words officially legalized is item 3, the manufacturer registration certificate. Conflating the two adds weeks of processing time and several fees out of thin air. The correct course is to confirm in writing with the accepting window which issuing body it requires and whether certification is needed.

Insight 4 | The real risk is discovering, after signing, that the content does not match the facts. Such documents are usually drafted by the company itself, and once signed and stamped they constitute written evidence of the company’s declaration of intent. If subsequent trading facts diverge from the document, the company faces not only problems in Iraq but also regulatory scrutiny at home and breach-of-contract risk. The first step must therefore be internal verification: shareholding structure, supply chain, existing customers and distributors, and licensing-department requirements. GRZAN recommends that the final text be issued by legal counsel rather than the project execution team.

Insight 5 | The order of handling a conflict must be planned. If verification reveals an inconsistency with the requirement: first, declare truthfully, keep written records, and make no untruthful statement; second, send a formal letter to the Iraqi purchaser, agent or accepting authority explaining the actual situation and asking in writing whether an alternative text is acceptable; third, take advice from a lawyer familiar with local practice; fourth, sign nothing inconsistent with the facts until the answer is clear. GRZAN does not participate in any practice of the change-the-letterhead or third-country-transit type.

4. Practical recommendations

• Place this requirement on the compliance review list at the project initiation stage and have the company’s head of legal confirm acceptability; the characterization must be completed before any Iraqi contract is signed.
• Have the text signed by the legal representative and stamped with the company seal, primarily in English with an Arabic translation where necessary, and keep scans of the originals with the signing dates.
• Confirm in writing the issuing body and format of the document. Practical estimate: the so-called templates are mostly drafted by the individual accepting units (no official provision found).
• State in the agency agreement that where the other party demands documents beyond the six-item list, it must first provide a written basis, with costs and delays borne by the demanding party.
• Archive correspondence, the other party’s replies and internal legal opinions together, retaining them for no less than the validity period plus five years.

5. Verification checklist

• □ Check the spelling and position of Section D item 5 in the list and confirm its parallel standing with items 2 through 6.
• □ Request the current template and issuing-body requirements in writing from the Registration Department or the accepting window, and keep the written reply.
• □ Search whether the Iraqi Official Gazette has published a ministerial instruction involving this requirement; where no local channel exists, mark it as pending verification.
• □ Have the company’s legal team complete an internal fact check, covering shareholding, supply chain and distribution relationships, and record the written conclusion.
• □ Obtain professional legal advice in the place of service to confirm the compliance of issuing such a declaration.
• □ Re-check whether the agency or distribution agreement covers the allocation of costs and delays for additional document demands.
• □ Re-verify whether the official documents cited in this article have been replaced by subsequent instructions or resolutions (verification baseline date of this article: October 29, 2026).

Regulatory information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iraqi market. Our team manages federal and Kurdistan registration applications, prepares reference-country dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com